BioHarvest (BHST) Q4 2025 Earnings Transcript

BioHarvest Sciences reported Q4 revenue of $9.1 million, up 25% year over year, with gross margin improving 100 bps to 58% and adjusted EBITDA swinging to a $0.5 million gain from a $1.8 million loss. Full-year revenue rose 37% to $34.5 million, while cash increased to $23 million from $2.4 million a year earlier. Management guided 2026 external CDMO revenue to $4 million-$6 million and said D2C profitability is expected this year, supported by the VINIA BloodFlow Hydration launch and a shift toward digital marketing and Health Pros.

Analysis

The market is likely underestimating the asymmetry in this setup: the consumer business is becoming a cash-generative flywheel, while the CDMO is still being treated like a cost center even though it is effectively building a portfolio of call options on multiple end markets. The key second-order effect is that better unit economics in D2C can subsidize a faster build-out of the partner-development platform without an immediate balance-sheet stress event, so the company can spend into growth while still de-risking solvency. That reduces near-term financing risk, but it also means the equity story will stay valuation-challenged until investors see repeatable conversion from Stage 1 milestones into Stage 2/3 revenue.

The bigger operating lever is distribution efficiency, not product novelty. Shifting acquisition away from legacy channels into digital and affiliate-led cohorts should improve payback periods if the company can hold CAC flat while expanding to younger users; that could re-rate the D2C franchise from a niche supplement brand to a more scalable subscription platform. The hidden risk is that this transition is being tested during a period of elevated marketing spend and multiple simultaneous launches, so execution noise could obscure underlying demand until late Q2 or Q3.

The CDMO pipeline is the most interesting optionality, but the timing is long-dated and easy to misread. The fragrance and saffron assets only matter if they progress beyond scientific milestones into industrial repeatability, and that is where most biotech-adjacent platform stories fail: not discovery, but scale-up, customer commitment, and time-to-revenue. The contrarian read is that investors should not pay for the headline pipeline today; they should pay for the growing evidence that the organization can repeatedly turn one platform into multiple monetizable formats with a lower marginal acquisition cost and a more durable moat than the market is currently assigning.

Key Decisions for Investors

• Long BHST as a small-cap growth optionality trade only on weakness, with a 6-12 month horizon; thesis is that Q2/Q3 operating inflection and a better CAC mix can drive a multiple re-rating before CDMO revenue fully contributes.
• Use call spreads instead of stock if liquidity allows: buy BHST 6-9 month calls and sell higher-strike calls to express upside from D2C leverage while capping exposure to execution misses and dilution risk.
• Avoid chasing after headline CDMO announcements; wait for evidence of Stage 2 conversion or repeat external customer revenue before adding, because scientific milestones alone rarely translate into near-term equity value.
• Pair long BHST against a basket of slower-moving consumer-health names with weaker direct subscription economics, betting that BHST’s mix shift and affiliate channel scaling can compress the valuation gap over the next 2 quarters.